MedTrace Logo

Sarcopenia and Diabetes Mellitus

NCT04407819 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2020-05-29

No results posted yet for this study

Summary

The association of diabetes mellitus type 2 (T2DM) with sarcopenia has not been adequately investigated. Sarcopenia is characterized by progressive and generalized loss of skeletal muscle mass which may affect performance.

Conditions

Interventions

RADIATION

WHOLE BODY DXA

Muscle mass was estimated by using the whole body DXA (Hologic Horizon W)

Sponsors & Collaborators

  • University of Thessaly

    collaborator OTHER

  • Dionyssiotis, Yannis, M.D.

    lead INDIV

Principal Investigators

  • Yannis Dionyssiotis, MD, PhD · Foundation for Care of Neurological Illnesses, Greece

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-20
Primary Completion
2018-07-31
Completion
2018-09-22

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04407819 on ClinicalTrials.gov